Assessment of early therapy response with 18F-FLT PET in glioblastoma multiforme

Clinical Nuclear Medicine

Volumn 39, Issue 10, 2014, Pages e431-e432

  Oborski, Matthew J ^a,b   Demirci, Emre ^a,c   Laymon, Charles M ^a,b   Lieberman, Frank S ^d   Mountz, James M ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c ISTANBUL UNIVERSITY   (Turkey)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

FLT PET glioblastoma multiforme; Therapy response assessment

Indexed keywords

3' FLUOROTHYMIDINE F 18; GADOLINIUM; TEMOZOLOMIDE; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; 3' FLUOROTHYMIDINE; RADIOPHARMACEUTICAL AGENT;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER RADIOTHERAPY; CASE REPORT; CLINICAL ASSESSMENT; FEMALE; FOLLOW UP; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PARIETAL LOBE; POSITRON EMISSION TOMOGRAPHY; TREATMENT RESPONSE; TUMOR BIOPSY; BRAIN NEOPLASMS; DIAGNOSTIC USE; SCINTISCANNING; TREATMENT OUTCOME;

BRAIN NEOPLASMS; DIDEOXYNUCLEOSIDES; FEMALE; GLIOBLASTOMA; HUMANS; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TREATMENT OUTCOME;

EID: 84924423175     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0000000000000321     Document Type: Article

References (8)

1. Chen W, Cloughesy T, Kamdar N, et al. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG. J Nucl Med. 2005;46:945-952.
2. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-996.
3. Combs SE, Wagner J, Bischof M, et al. Postoperative treatment of primary glioblastoma multiforme with radiation and concomitant temozolomide in elderly patients. Int J Radiat Oncol Biol Phys. 2008;70:987-992.
4. Herholz K, Langen K-J, Schiepers C, et al. Brain tumors. Semin Nucl Med. 2012;42:356-370.
5. Schwarzenberg J, Czernin J, Cloughesy TF, et al. 3-deoxy-3-18F-fluorothymidine PET and MRI for early survival predictions in patients with recurrent malignant glioma treated with bevacizumab. J NuclMed. 2012;53:29-36.
6. Chen W, Delaloye S, Silverman DHS, et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol. 2007;25:4714-4721.
7. Dhermain FG, Hau P, Lanfermann H, et al. Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas. Lancet Neurol. 2010;9:906-920.
8. Stupp R, Tonn J-C, Brada M, et al. High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21:v190-v193.